2019 Press Releases

Home»2019 Press Releases
15 11, 2019

Eiger to Present at Jefferies 2019 London Healthcare Conference

2019-11-15T17:27:31+00:00

Eiger to Present at Jefferies 2019 London Healthcare Conference PALO ALTO, Calif. – November 15, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies 2019 London Healthcare Conference on November [...]

Eiger to Present at Jefferies 2019 London Healthcare Conference2019-11-15T17:27:31+00:00
12 11, 2019

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results

2019-11-12T21:55:21+00:00

Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 Median Decline of HDV RNA: -3.4 Log at Week 24 95% of Patients Achieve > [...]

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results2019-11-12T21:55:21+00:00
7 11, 2019

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

2019-11-07T21:42:42+00:00

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD First-Ever Phase 3 HDV International D-LIVR Study Enrolling and Dosing Strong Balance Sheet with $109.9M in Cash & Investments PALO ALTO, [...]

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update2019-11-07T21:42:42+00:00
21 10, 2019

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019

2019-10-21T14:08:32+00:00

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019rectors >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24Median Decline of HDV RNA: -3.4 Log at Week 2495% of Patients Achieve >2 Log Decline in HDV [...]

Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 20192019-10-21T14:08:32+00:00
28 09, 2019

Eiger to Present at Cantor 2019 Global Healthcare Conference

2019-09-28T15:38:30+00:00

Eiger to Present at Cantor 2019 Global Healthcare Conference PALO ALTO, Calif. – September 27, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Cantor 2019 Global Healthcare Conference on October [...]

Eiger to Present at Cantor 2019 Global Healthcare Conference2019-09-28T15:38:30+00:00
29 08, 2019

Eiger BioPharmaceuticals to Participate in September Conferences

2019-08-29T20:16:25+00:00

Eiger BioPharmaceuticals to Participate in September Conferences PALO ALTO, Calif. – August 29, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September: Baird 2019 Global Healthcare Conference at the [...]

Eiger BioPharmaceuticals to Participate in September Conferences2019-08-29T20:16:25+00:00
20 08, 2019

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection

2019-08-20T12:48:11+00:00

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., August 20, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and [...]

Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection2019-08-20T12:48:11+00:00
6 08, 2019

Eiger BioPharmaceuticals to Participate in Investor Conferences in August

2019-08-06T18:37:29+00:00

Eiger BioPharmaceuticals to Participate in Investor Conferences in August PALO ALTO, Calif. – August 5, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two upcoming investor conferences in August. BTIG Biotechnology Conference at St. Regis [...]

Eiger BioPharmaceuticals to Participate in Investor Conferences in August2019-08-06T18:37:29+00:00
17 06, 2019

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)

2019-06-17T20:57:19+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., June 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)2019-06-17T20:57:19+00:00
10 06, 2019

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs

2019-06-10T13:59:43+00:00

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PALO ALTO, Calif., June 10, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, today announced the appointment of Mark Mannebach, PhD, RPh as Vice President [...]

Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs2019-06-10T13:59:43+00:00